Prevalence of Fabry Disease in Patients With Cryptogenic Strokes: A Systematic Review

Juan Fernando Ortiz 1, Jashank Parwani 2, Paul W. Millhouse 3, Ahmed Eissa-Garcés 4, Gashaw Hassen 5, 6, Victor D. Cuenca 7, Ivan Mateo Alzamora 8, Mahika Khurana 9, Domenica Herrera-Bucheli 10, Abbas Altaminii 10, Adam Atoot 11, Wilson Cueva 1

1. Neurology, Larkin Community Hospital, Miami, USA
2. Neurology, Lokmanya Tilak Municipal Medical College, Mumbai, IND
3. General Practice, Drexel University College of Medicine, Philadelphia, USA
4. Neurology, Universidad San Francisco de Quito, Quito, ECU
5. Medicine and Surgery, University of Parma, Parma, ITA
6. Progressive Care Unit, Mercy Medical Center, Baltimore, USA
7. Medicine, Universidad San Francisco de Quito, Quito, ECU
8. Public Health, University of California Berkeley, Berkeley, USA
9. Medicine, Universidad Internacional del Ecuador, Quito, ECU
10. Emergency Medicine, Amiri Hospital, Kuwait City, KWT
11. Internal Medicine, Palisades Medical Center, North Bergen, USA

Corresponding author: Juan Fernando Ortiz, sumjuanfer41@gmail.com

Abstract

Fabry disease (FD) is an X-linked disorder involving multiple organs. Stroke is a serious and frequent complication of FD. Cryptogenic stroke is a common presentation of FD, especially in the young population. The etiology of cryptogenic stroke is highly variable and difficult to assess, frequently leaving patients without a primary diagnosis. We conducted a systematic review to investigate the pooled prevalence of FD among patients with cryptogenic stroke, or patients with FD in whom a stroke was the presenting condition. English-language studies involving humans published in the last 20 years were included in this systematic review. FD was more common in male patients and tended to present at an earlier age. The frequency of hemorrhagic and ischemic strokes in this population was similar to that in the general population. There was a high rate of stroke recurrence in the study sample, even among patients undergoing enzyme replacement therapy. We conclude that screening for FD in patients with cryptogenic stroke is low yield and not cost-effective. However, it may be worthwhile to screen for FD among patients with recurrent strokes.

Introduction And Background

Fabry disease (FD) is an X-linked lysosomal storage disorder caused by an inborn error in the glycosphingoglipid metabolic pathway, with deficient activity of the lysosomal enzyme alpha-galactosidase A that results in lysosomal accumulation of globotriaosylceramide (Gb3) in multiple organs [1]. Gb3 mainly accumulates in the endothelial, cardiac, renal, and dorsal root ganglion neuronal cells [2]. The prevalence of FD is approximately 1 in 117,000 individuals [1]. The majority of cases are reported in Caucasians, and most patients who present with symptoms are male [2]. There are different types of FD mutations on the alpha-galactosidase (GAL) gene which causes the disease, including point mutations (83.4%), missense mutations (50%), nonsense mutations (29.2%), frameshift mutations (16.6%), and splicing (4.2%) [1].

Suspicion of FD can come through family history, clinical manifestations, and lab abnormalities, with the diagnosis confirmed by biochemical and molecular genetic testing [3]. Neuroradiologic evaluation is done using T2-weighted MRI, fluid-attenuated inversion recovery (FLAIR), or via evidence of pulvinar hyperintensity on T1-weighted images. These lesions are present in one-third of patients and are very suggestive of the disease when the diagnosis is uncertain [4].

There are two types of FD, namely, classical and late-onset FD. The classical form occurs in hemizygous males or heterozygous females [5]. Classical FD initiates at a young age with the main symptoms including acroparesthesias, gastrointestinal disturbances, angioedemas, impaired sweating, and heat and cold intolerance [5]. Complications include hypertrophic cardiomyopathy, renal failure, and stroke [5]. Female heterozygotes are also symptomatic, especially when they have skewed X chromosome inactivation [5]. Patients with late-onset FD usually present in the third to the seventh decade of life. Most patients do not display the classical symptoms as just one organ may be affected. The level of enzyme activity ranges from 2% to 30% of the normal, and an accumulation of Gb3 on blood vessels may not be evident [6-8].

There is a dearth of large-scale studies on FD. Although many observational studies have described the prevalence of stroke and FD, most included small cohorts. To reduce bias and determine a more accurate record, a pooled analysis of observational studies is needed. In this review, we aim to determine the prevalence of FD in patients with cryptogenic stroke or first-time stroke. We further aim to consolidate the knowledge of cryptogenic stroke and FD, explore the pathophysiology of ischemic stroke in FD, investigate the use of enzyme replacement therapy (ERT) as a preventive measure for stroke recurrence, and explore the

How to cite this article
Ortiz J, Parwani J, Millhouse P W, et al. (November 08, 2021) Prevalence of Fabry Disease in Patients With Cryptogenic Strokes: A Systematic Review. Cureus 13(11): e19358. DOI 10.7759/cureus.19358
influence of gender among these patients.

**Review**

**Methodology**

**Protocol**

This systematic review was conducted following the Meta-Analysis of Observational Studies in Epidemiology (MOOSE) reporting guidelines [9].

**Eligibility Criteria and Study Selection**

Only observational studies conducted among human subjects in the last 25 years and written in the English language with the full report available were included in this review. We excluded case reports, systematic reviews, literature reviews, and meta-analyses that did not fulfill the study criteria. We included studies reporting on patients aged 18 to 60. Additionally, any articles that were not deemed relevant to the study parameters were excluded.

After screening the results, only articles with at least one of the following characteristics were included: patients with cryptogenic ischemic stroke or stroke presenting as the first symptom in whom measurement of either plasma levels of Gb3 with $\alpha$-GAL-A gene sequencing, or $\alpha$-GAL-A enzyme levels, was done. Patients with a pathogenic mutation were compared to those with a mutation of unknown pathogenicity. Our primary aim was to calculate the prevalence of FD in cryptogenic stroke. The secondary aim was to describe the characteristics of patients with cryptogenic stroke who were diagnosed with FD. We investigated the mutation type, stroke type, and prognosis of each of these patients.

**Database and Search Strategy**

For this systematic review, we used PubMed as a database. The search was done between July 25, 2020, and July 18, 2021. We used the following combination of search terms: "Fabry disease"[Title/Abstract] AND "stroke"[Title/Abstract] OR ("cryptogenic stroke"[Title/Abstract] AND "Fabry disease"[Title/Abstract]). In addition to PubMed, Embase and Scopus were searched, but it did not result in any additional studies that fit the criteria.

**Data Extraction**

The following information was collected: author, year of publication, country of publication, study type, methodology, outcomes, and prevalence of FD in stroke patients. For all patients who presented with stroke and had a diagnosis of FD, the following additional information was extracted: type of mutation, Gb3 levels or plasma $\alpha$-GAL-A levels, type of stroke, and prognosis.

**Bias Analysis**

To assess and minimize bias the risk of bias in non-randomized studies (ROBINS-I) tool for observational studies was used [10].

**Results**

Figure 1 shows a flowchart with the results of this systematic review.
A total of 11 studies from 10 different countries were included. Probable and definitive diagnosis was assessed in the final prevalence among the observational studies. Table 1 shows the characteristics and outcomes of the cohorts investigated in this systematic review [1,2,11-19].

| Author, year of publication, country | Study type            | Methodology                                                                 | Outcome                                                                                           |
|-------------------------------------|-----------------------|-----------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|
| Duboc et al., 2011, Canada [2]      | Single-center cohort study | Data were gathered from patients aged 16-55 years with cryptogenic stroke in a single center. α-GAL-A gene sequencing and plasma Gb3 levels were measured | Seven patients had a positive screening for FD (five women and two men) carrying mutations of undetermined pathogenicity. One patient had a mutation of unknown pathogenicity and another patient had confirmed pathogenic mutation and elevated levels of Gb3. Prevalence: 2/101 (1.9%) patients with cryptogenic stroke had FD |
| Lanthier et al., 2017, Canada [11] | Prospective cohort study | Enrolled patients aged 18-55 with either ischemic stroke or TIA. α-GAL-A gene was measured. NIHSS was measured acutely and mRS at seven days and six months | There were 8/397 patients who had a positive screening for FD. Six patients had multiple neutral genetic variants of the gene. One patient presented with a single disease-neutral variant (p.D313Y). Another patient presented with GVUS (p.R118C). The prevalence of FD was 1 in 395 (0.3%) |
| Gündoğdu et al., 2017, Turkey [1]   | Prospective cohort study | 484 patients aged 18-55 were enrolled from the city of Sakarya with acute ischemic stroke. Ischemic stroke was confirmed by CT and MRI. α-GAL-A was measured. Low enzyme levels of <1.2 μmol/L/hour were indicative of FD. DNA sequencing for GAL missense mutation for those with low enzyme activity was also done | 484 patients with ischemic stroke were enrolled. 67 patients fulfilled the criteria of the study. 13 were lost to follow-up; hence, 54 patients were finally included in the study. Three (two males and one female) patients had low levels of α-GAL-A enzyme activity. The female had no gene mutation despite having low levels of the enzyme. The two male patients presented pathogenic mutation of FD (missense mutation). The prevalence of FD in this cohort was 2/67 (3.7%) |

**Study Characteristics and Outcomes**

PRISMA: Preferred Reporting Items for Systematic reviews and Meta-Analyses
### TABLE 1: Study type, methods, and outcomes of the studies.

| Study Authors, Country, Year | Study Type, Methods, and Outcomes of the Studies | Summary |
|-----------------------------|------------------------------------------------|---------|
| Malave et al., 2020, Australia [12] | Prospective multicenter cohort study | The study included 326 patients aged 18-55 with cryptogenic stroke during 2014-2015. The levels of α-GAL-A enzyme activity followed by gene analysis and lyso-Gb3 levels were conducted on 58/326 patients who consented for participation in the study. | Out of 326 patients who met the inclusion criteria, 58 provided consent. However, six failed the initial screening blood draw and two withdrew consent. There were 50 participants who underwent enzyme/genetic analysis. 47% (n = 23) were females and 53% (n = 27) were males. Although 7/27 males showed low enzyme levels, genetic analysis did not reveal FD. Among the 23 females, only one had a pathologic FD on genetic analysis. Overall, the prevalence of FD was 1.72% in this cohort 1/58 (1.72%) |
| Rolfs et al., 2005, Germany [13] | Multicenter prospective cohort study | Between February 2001 and December 2004, 721 German adults aged 18-55 in 27 clinical departments in Germany suffering from cryptogenic stroke were screened for FD. The plasma α-GAL-A activity in men was measured, followed by sequencing of the entire gene in those with low enzyme activity. By contrast, the entire α-GAL gene was genetically screened for mutations in women even if enzyme activity was normal. | 32 patients had reduced activity of the enzyme (22 men 10 women). Out of them, 28 patients (21 men and 7 women) had a pathogenic mutation of the gene. Prevalence in males was 4.9%, and prevalence in females was 2.4%. Strokes were more common in the verteobasilar artery (42.9%). The total prevalence in this cohort was 28/721 (3.8%) |
| Kinoshi et al., 2012, Japan [14] | Multicenter prospective cohort study | From April 2015 to December 2016, 516 young patients (<60 years) with either ischemic or hemorrhagic stroke were enrolled in the study. α-GAL enzyme activity and Gb3 levels were measured followed by α-GAL-A gene sequencing | 110 patients had cryptogenic strokes. Five patients (one woman and four men) had low α-GAL-A enzyme activity. Two patients had a mutation of unknown pathogenicity. No pathogenic mutation was found despite five patients having low levels of α-GAL-A enzyme activity. The prevalence of FD was 0/110 (0%) in this cohort. |
| Alhazaa et al., 2020, Saudi Arabia [15] | Single-center cohort study | 51 patients aged 18-55 with cryptogenic stroke were included in the study. α-GAL-A enzyme activity was measured, and genetic testing was performed in patients with abnormal results. | 500 patients were screened in this study, but only 51 were included. One case had borderline levels of the enzyme, but the genetic test revealed no genetic mutation of FD. Prevalence in this cohort was 0/51 (0%) |
| Brouns et al., 2007, Belgium [16] | Multicenter cohort Study | During January 2000 and December 2004, 103 patients with cryptogenic stroke aged 16-60 were screened for FD. Measurement of the α-GAL-A enzyme was followed by genetic testing in males with abnormal results. | 103 patients were included in the cohort. Three patients (two women and one man) had abnormal levels of the α-GAL-A enzyme. The same three patients had normal genetic testing. No patient was identified with FD. The prevalence in this cohort was 0% |
| Sarikaya et al., 2012, Switzerland [17] | Cohort study | Between January 2006 and October 2009, 150 patients were recruited, with a mean age of 43. Enzyme activity was measured in all patients. Genetic analysis was done in all females and males with low enzyme levels. | 150 patients met the inclusion criteria of the study. Nine patients had low enzymes levels (six men and three women). A nonpathogenic mutation was found on genetic analysis of the nine patients with low enzyme activity. However, pathogenic mutation was not found. Hence, the prevalence in this cohort was 0% |
| Reinsin et al., 2018, Argentina [18] | Cohort study | Young patients in Argentina with TIA, ischemic stroke, or hemorrhagic stroke between 2011 and 2015 were enrolled. α-GAL-A levels were measured in all patients. Males with low levels of the enzyme and all females underwent genetic sequencing of the gene. | 311 patients were enrolled in the study. Ischemic events occurred in 89%, and 11% had a hemorrhagic event. Only one patient had the pathogenic mutation of FD. Another patient had a mutation of unclear significance. Both were missense mutations. Prevalence in this cohort was 2/311 (0.64%) |
| Wozniak et al., 2010, United States [19] | Cohort study. | 550 men aged 15-49 years with their first ischemic stroke were enrolled in the study. The levels of α-GAL-A were measured in all patients. Patients with lower levels of the enzyme underwent genetic analysis. | 154 out of 550 patients with stroke had a cryptogenic stroke. 110 patients had low levels of the enzyme. Genetic testing on these patients showed a pathogenic mutation in one patient and a mutation of undefined significance in another. Hence, the prevalence was 1/154 (0.65%) |

FD: Fabry disease; α-GAL-A: alpha-galactosidase-A; Gb3: globotriaosylceramide; TIA: transient ischemic attack; NIHSS: National Institutes of Health Stroke Scale; mRS: modified Rankin scale; GVUS: genetic variants of unknown significance; CT: computed tomography; MRI: magnetic resonance imaging.
We found 36 patients with cryptogenic stroke, or stroke as a presenting condition, in the 11 studies involving 1,986 patients in various cohort studies. The total prevalence of FD among these studies was 1.81%.

*Stroke Characteristics of Patients With Fabry Disease*

Table 2 shows the age and sex, mutation, Gb3 levels and enzyme activity, infarct type, outcome (second stroke), long-term outcome, and treatment of patients included in the studies [1,2,11-13,19].
| Author, year | Age and sex | Mutation | Gb3 levels and enzyme activity | Infarct | Outcome (second stroke) | Outcome | Treatment |
|--------------|-------------|----------|-------------------------------|--------|------------------------|---------|-----------|
| Dubuc et al., 2012 [2] | 40 M | Unknown pathogenicity (GVUS) | Mildly elevated; Gb3 after the second stroke was normal | Nonlacunar vertebro basilar | 42 months later, he had an infarct in the carotid artery territory | Bad functional | No ERT, antiplatelet drugs |
| Lanthier et al., 2017 [11] | 41 F | Pathogenic | Not described | Lacunar ischemic stroke | Two TIAs and two recurrent nonlacunar ischemic strokes in the subsequent 63 months of follow-up | Memory impairment | Aspirin, ERT after stroke |
| Lanthier et al., 2017 [11] | 55 M | GVUS (p.R118C) | Normal (Gb3) | Lacunar (left basal ganglia and subcortical infarctions). No leukoaraiosis | He had no further cerebrovascular events at seven months | mRS had improved from 3 at baseline to 1 at six months. | No information available |
| Rolfs et al., 2005 [13] | 39 F | Single disease-neutral | Normal (Gb3) | Lacunar (acute left thalamic lacune) | No recurrent cerebrovascular events on aspirin and atorvastatin prophylaxis | No information available | No information available |
| Malavera et al., 2020 [12] | 38.4 M | o-GAL gene | Men: o-GAL-A high or low + Gb3 | MCA infarction: 28.6% (6/21). PCA infarction: 14.1% (3/21). Vertebrobasilar artery: 9/21 (42.9%). Hemorrhage: 5/7 (71.4%) | 10 cases of multiple cerebrovascular events | Hemiparesis, ataxia, dysarthria, pathologic nystagmus | No information regarding ERT |
| Malavera et al., 2020 [12] | 40.3 F | Women: o-GAL-A high or normal + Gb3 | MCA infarction: 42.9% (3/7). PCA infarction: 14.3% (1/7). Vertebrobasilar artery: 47 (67.1%). Hemorrhage: 1/7 (14.3%). Vertebrobasilar infarction: 42.9% | Two cases of multiple cerebrovascular events | Information not available | Information not available |
| Gündoğdu et al., 2017 [1] | 49 F | Pathogenic | Normal levels of Gb 3 | Intraparenchymal hemorrhage | No recurrent cerebrovascular events | Information not available | Secondary prevention with antiplatelets and statins |
| Wizniak et al., 2010 [19] | 24 M | Pathogenic | Low o-GAL-A activity (0.1 μmol/L/hour) | Right basal ganglia infarction. MRI revealed WMHs in both hemispheres and lacunar infarctions in the thalamus, brain stem, and parietal lobe | No further cerebrovascular events at six months | Cardiomyopathy, CKD, neuropathic pain, hypohidrosis, and GI disease | ERT |
| Wizniak et al., 2010 [19] | 43 M | Pathogenic | Low o-GAL-A activity (0.1 μmol/L/hour) | Lacunar infarction in the pons (same place as the previous stroke) | Second lacunar stroke | Remained with left-sided paralysis. | ERT |

**TABLE 2: Characteristics of the patients with FD and stroke.**

Gb3: globotriaosylceramide; GVUS: genetic variants of unknown significance; ERT: enzyme replacement therapy; TIA: transient ischemic attack; mRS: modified Rankin scale; MCA: middle cerebral artery; PCA: posterior cerebral artery; o-GAL-A: alpha-galactosidase-A; MRI: magnetic resonance imaging; WMHs: white matter hyperintensities; CKD: chronic kidney disease; GI: gastrointestinal; FD: Fabry disease
Among the stroke patients, there were 32 ischemic infarcts (86.48%) and five hemorrhagic infarcts (13.51%). The number of patients with re-infarctions was 16 (43.24%). The mean age of males was 37.24 and for females was 41.11 years. In general, Gb3 levels were normal or mildly elevated in patients for whom the value was available. Measurement of α-GAL-A activity was a more sensitive marker than Gb3 level. Among the cohorts, there was heterogeneity in the way the different studies described mutations. We included patients with pathogenic mutations, mutations of unknown pathogenicity, and neutral mutations with related pathogenicity.

Study Limitations

Table 3 shows the bias of the studies included in this systematic review [1,2,11-16,19].

| Author, year          | Confounding | Selection of participants | Classification | Deviations | Missing data | Measurements | Selection of reported results |
|-----------------------|-------------|---------------------------|----------------|------------|--------------|--------------|-------------------------------|
| Gündoğdu et al., 2017 [1] | Medium risk | Moderate risk             | Low risk        | Low risk   | Moderate risk | Low risk      | Low risk                      |
| Dubuc et al., 2012 [2]   | Low risk    | High risk                 | Low risk        | Low risk   | Low risk     | Low risk      | Low risk                      |
| Lanthier et al., 2017 [11] | Low risk  | Moderate risk             | Low risk        | Low risk   | Moderate risk | Low risk      | Low risk                      |
| Malavera et al., 2020 [12] | Low risk    | Moderate risk             | Low risk        | Low risk   | Low risk     | Moderate risk | Low risk                      |
| Rolfs et al., 2005 [13]   | Low risk    | Low risk                  | Moderate risk   | Low risk   | Moderate risk | Low risk      | Low risk                      |
| Kinoshita et al., 2018 [14] | Low risk    | Moderate risk             | Low risk        | Low risk   | Moderate risk | Low risk      | Low risk                      |
| Alhazzaa et al., 2020 [15] | Low risk    | High risk                 | Low risk        | Low risk   | Moderate risk | Low risk      | Moderate risk                 |
| Brouns et al., 2007 [16]   | Low risk    | Moderate risk             | Low risk        | Low risk   | Moderate risk | Low risk      | Low risk                      |
| Wozniak et al., 2010 [19]   | Low risk    | High risk                 | Low risk        | Low risk   | Moderate risk | Low risk      | Moderate risk                 |

**TABLE 3: Bias analysis using ROBINS-I tool.**

ROBINS-I: risk of bias in non-randomized studies of interventions

In five studies, the authors found that the sample was too small to reach statistical power [1,11,14-16]. In the study by Kinoshita et al., genetic analysis was not conducted in each patient, which could lead to a measurement bias [14]. Lanthier et al. stated that they could have missed some FD cases as all patients did not undergo genetic analysis [11]. In the study by Alhazzaa et al., the inclusion criteria were somewhat restrictive and more than half of the cohort suffered regular vascular risk factors such as diabetes, hypertension, and/or dyslipidemia, which could have contributed to the stroke. Further, in the study by Brouns et al., genetic testing was not performed among women which could introduce bias as the enzyme levels in female FD patients are often normal (false negatives) [16]. Finally, this study did not include cases of lacunar infarcts which further limited their numbers [15].

Discussion

**Pathophysiology of Stroke in Patients With Fabry Disease**

Most studies agree that the accumulation of glycosphingolipids in vascular endothelium causes disturbances in vasoreactivity and autoregulation, increasing the likelihood of stroke. Other theories have also been suggested in the literature. According to Sawada et al., vasospasm may play an important role in the pathophysiological mechanism of stroke in FD patients. This is supported by the high incidence of spastic coronary angina seen in FD [20]. Hilz et al. extensively studied stroke mechanisms and concluded that reduced cerebral blood flow velocities and impaired autoregulation are key factors [21]. A review by Rombach et al. suggested that smooth muscle cells are primarily involved in the vasculopathy of FD and that, in the early stages of Fabry vasculopathy, angiotensin II production becomes upregulated [22]. Further, other mechanisms such as increased reactive oxygen species production, enhanced nitric oxide levels, and
the presence of a prothrombotic state have also been identified to contribute to the development of stroke [23]. Lastly, cardiac arrhythmias, hypertrophic cardiomyopathy and myocardial infarction may lead to stroke in patients with FD [14].

Stroke in Patients with Fabry Disease and Prevalence of Fabry Disease in all Types of Strokes

FD affects both the peripheral nervous system and the central nervous system (CNS). The CNS symptoms in FD include psychiatric manifestations, headaches, and strokes [20]. In this systematic review, we only included information on cryptic strokes or patients with stroke as the first sign of presentation; therefore, all patients in our sample pool were, by definition, late-onset FD patients. Stroke is approximately 12 times more common in patients with FD than in the general population [1]. Approximately 25% of FD patients develop transient ischemic attack and stroke at a mean age of 40 (PM1) [24]. From the FD database (PM2), 138 out of 2,446 patients developed stroke [24]. The median age of first-time stroke was 39 years in males and 45.7 in females. Ischemic stroke was seen in 86.8% of the patients and hemorrhagic stroke in 15.9% of the patients, which is very similar to the general population [24]. In the same study, 70.4% of the strokes were lacunar [24]. Five of 52 females (8.6%) and 45 of 86 males (50%) who experienced stroke did not have the diagnosis of FD [25]. In comparison to our review, the rates of ischemic and hemorrhagic strokes were similar, and the age of presentation and the ratio of males to females were also similar. Table 4 lists the studies that included all types of strokes [25-27].

| Author, year, country | Number of cases | Prevalence of FD |
|------------------------|----------------|------------------|
| Lee et al., 2019, Taiwan [25] | 1,000 stroke patients: 661 ischemic strokes and 339 hemorrhagic strokes. | Two male patients with ischemic stroke were found to have a pathogenic mutation of FD. Overall prevalence was 0.2 for all strokes and 0.3 for ischemic strokes. |
| Rolfs et al., 2013, Europe [26] | 5,023 patients with CVS from 15 different countries were enrolled in this study. Ischemic stroke: 3,396, hemorrhagic stroke: 271, transient ischemic attack: 1,071 | Definitive FD was found in 0.5% of the sample (N = 27). Probable FD was found in 0.3% of patients (N = 18). |
| Song et al., (2016), China [27] | 357 patients underwent tests for α-GAL-A activity. 293 out of 357 patients with cerebral infarction and 64 out of 357 patients with transient ischemic stroke were screened for mutations in the enzyme | No patients with FD were found (prevalence: 0%). |

**TABLE 4: Studies of all type of strokes and FD.**

FD: Fabry disease; CVS: cardiovascular stroke; α-GAL-A: alpha-galactosidase-A

Prevalence in studies that included all types of strokes ranged from 0% to 0.5% compared to our pooled analysis (0-3.88%), suggesting that the prevalence of FD is higher with cryptogenic strokes than other stroke types. The study by Rolfs et al. reported the highest prevalence among all the studies [26]. Most studies included only patients who developed a stroke for the first time. However, the study by Rolfs et al. also included patients with recurrent strokes, suggesting that the prevalence of FD among patients with recurrent stroke is higher compared to the general population.

Screening Fabry Disease in Patients With Ischemic Stroke

Early recognition of FD in patients with cryptogenic stroke is critical to prevent recurrent strokes [11]. However, most studies agree that generalized screening for FD among these patients is expensive and has low yield due to the low disease prevalence [2]. However, patients with recurrent strokes in some cohorts had higher rates of FD, suggesting that screening could be beneficial in this population [11,26].

Females tend to have normal levels of α-GAL-A enzyme activity due to the random inactivation of chromosome X, making gene sequencing more essential among females [12]. Measuring the levels of Gb3 has shown to be a more effective screening tool than α-GAL-A enzyme activity among females. However, measuring the enzyme activity is a more sensitive test in males [14]. Gündoğdu et al. suggested that screening of FD in countries with a high prevalence of genetic disease could be beneficial [1]. Moreover, recognizing neutral mutations is vital to ensure that patients do not go through unnecessary investigations
and treatment [11]. Alhazzaa et al. also argued that screening for FD in patients with cryptogenic stroke is not cost-effective [15].

**Management and Role of Enzyme Replacement Therapy in the Treatment of Fabry Disease**

ERT has been shown to improve kidney function, reduce cardiomyopathy, and improve circulation by increasing NO levels. However, the prevention of stroke with ERT has not been demonstrated [20]. There is no consensus regarding when to initiate ERT in FD. Some experts suggest that it should be started among men as soon as the diagnosis is made and among women if clinical manifestations are present. The initial consensus suggests that ERT does not prevent stroke. However, a pooled analysis including seven cohort studies and two randomized controlled trials indicated that ERT has a beneficial effect in preventing stroke and stroke recurrence in patients with genetically, enzymatically, and/or biopsy-proven FD [28]. In one report, stroke recurrence rates were 0.082 in the ERT group versus 0.160 in the control group, with the difference being statistically significant [28]. The effects of ERT occurred gradually, but prevented strokes in the long term [29]. Sheng et al. suggested that women should consider initiating ERT at the time of FD diagnosis because stroke often occurs before the diagnosis is made [28].

Rolfs et al. argued that patients should be on a more effective antiplatelet medication such as clopidogrel or a combination of dipyridamole and aspirin [13]. Only two studies in our systematic review described patients who received ERT after stroke. In these studies, three patients received ERT but two developed stroke recurrence. We recommend further research to help determine whether ERT prevents recurrent strokes in patients with genetic stroke due to FD.

**Conclusions**

Although the pathogenesis of stroke in FD remains unclear, various mechanisms such as vasospasm, reduced cerebral blood flow velocity, abnormal autoregulation and upregulation of angiotensin II, and accumulation of glycosphingolipids in vascular endothelium have been proposed.

The prevalence of cryptogenic stroke in FD is highly variable among studies. However, compared to single strokes, FD was seen more commonly in patients with recurrent strokes. Hence, it may be useful to perform FD screening in such cases. Screening should be done by determining α-GAL-A enzyme activity in males and plasma Gb3 levels in females, followed by α-GAL-A gene sequencing for confirmation.

Finally, we conclude that ERT may decrease the recurrence of stroke in FD patients in the long term. Despite the initial consensus that ERT does not prevent stroke, the difference was statistically significant in recent systematic reviews.

**Additional Information**

**Disclosures**

Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors declare that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: In all authors have declared that there are no other relationships or activities that could have influenced the submitted work.

**References**

1. Gündoğdu AA, Kutan D, Alemdar M: The frequency of Fabry disease among young cryptogenic stroke patients in the city of Sakarya. J Stroke Cerebrovasc Dis. 2017, 26:1534-40. 10.1016/j.jstrokecerebrovasdis.2017.02.004
2. Dubus V, Moore DF, Giaia LC, Saponnik G, Selchen D, Lanthier S: Prevalence of Fabry disease in young patients with cryptogenic ischemic stroke. J Stroke Cerebrovasc Dis. 2015, 22:1288-92. 10.1016/j.jstrokecerebrovasdis.2012.10.005
3. Kok K, Zwiens KC, Boot RG, Overkleeft HS, Aerts JM, Artola M: Fabry disease: molecular basis, pathophysiology, diagnostics and potential therapeutic directions. Biomolecules. 2021, 11:271. 10.3390/biom11020271
4. Moore DF, Ye F, Schiffmann R, Butman JA: Increased signal intensity in the pulvinar on T1-weighted images: a pathognomonic MR imaging sign of Fabry disease. AJNR Am J Neuroradiol. 2003, 24:1096-101.
5. Cainelli F, Argandiykov D, Kaldarokov D, Mukanov M, Tran Thi Phuong L, Germain DP: Case report: first two identified cases of Fabry disease in Central Asia. Front Genet. 2021, 12:657824. 10.3389/fgene.2021.657824
6. Vardarli I, Rischpler C, Herrmann K, Weidemann F: Diagnosis and screening of patients with Fabry disease. Ther Clin Risk Manag. 2020, 16:551-9. 10.2147/TCRM.S247814
7. Ranieri M, Bedini G, Parai EA, Bersano A: Fabry disease: recognition, diagnosis, and treatment of neurological features. Curr Treat Options Neurol. 2016, 18:33. 10.1007/s11940-016-0414-5
8. Viana-Baptista M: Stroke and Fabry disease. J Neurol. 2012, 259:1019-28. 10.1007/s00415-011-6278-4
9. Brooke BS, Schwartz TA, Pawlik TM: MOOSE reporting guidelines for meta-analyses of observational
studies. JAMA Surg. 2021, 156:787-8. 10.1001/jamasurg.2021.0522
10. Sterne JA, Hernán MA, Reeves BC, et al.: ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016, 355:i4919. 10.1136/bmj.i4919
11. Lanthier S, Sapounik G, Lebovic G, Pope K, Selchen D, Moore DF: Prevalence of Fabry disease and outcomes in young Canadian patients with cryptogenic ischemic cerebrovascular events. Stroke. 2017, 48:1766-72. 10.1161/STROKEAHA.116.016085
12. Malavera A, Cadilhac DA, Thiis V, et al.: Screening for Fabry disease in young strokes in the Australian Stroke Clinical Registry (AuSCR). Front Neurol. 2020, 11:596420. 10.3389/fneur.2020.596420
13. Malavera A, Cadilhac DA, Thiis V, et al.: Prevalence of Fabry disease in young patients with cryptogenic stroke: a prospective study. Lancet. 2005, 366:1794-6. 10.1016/S0140-6736(05)6635-0
14. Kinoshiba N, Hosomi N, Matsuhashi H, et al.: Screening for Fabry disease in Japanese patients with young-onset stroke by measuring α-galactosidase A and globotriaosylphosphatidylserine. J Stroke Cerebrovasc Dis. 2018, 27:5563-9. 10.1016/j.jstrokecerebrovasdis.2018.08.025
15. Alhazaa MA, Mubarak A, Aljohani MA, Alqarni F, Alsharif R: The prevalence of Fabry disease among young patients with stroke. Cureus. 2020, 12:e9415. 10.7759/cureus.9415
16. Brouns R, Sospitalanday R, Braun J, et al.: Middelheim Fabry Study (MiFaS): a retrospective Belgian study on the prevalence of Fabry disease in young patients with cryptogenic stroke. Clin Neuroeurog. 2007, 109:479-84. 10.1007/s00415-007-0300-8
17. Sarikaya H, Yilmaz M, Munizera AR, Steinmann B, Baumgartner RW: Zurich Fabry study - prevalence of Fabry disease in young patients with first cryptogenic ischemic stroke or TIA. Eur J Neurol. 2012, 19:1421-6. 10.1111/j.1468-1331.2012.03673.x
18. Reisin RC, Mazziotti J, Cejas LL, et al.: Prevalence of Fabry disease in young patients with stroke in Argentina. J Stroke Cerebrovasc Dis. 2018, 27:575-82. 10.1016/j.jstrokecerebrovasdis.2017.09.045
19. Wozniak MA, Kittner SJ, Tuhrim S, et al.: Frequency of unrecognized Fabry disease among young European-American and African-American men with first ischemic stroke. Stroke. 2010, 41:78-81. 10.1161/STROKEAHA.109.558520
20. Sawada J, Nakagawa N, Kano K, et al.: Characteristics of neurological symptoms in adult Japanese patients with Fabry disease. Intern Med. 2021, 60:1819-26. 10.2169/internalmedicine.6420-20
21. Hila MJ, Kosterhui E, Bury M, Stepper H, Arndt T, Martal H: Reduced cerebral blood flow velocity and impaired cerebral autoregulation in patients with Fabry disease. J Neurol. 2004, 251:564-70. 10.1007/s00415-004-0364-9
22. Rombach SM, Twickler TB, Aerts JM, Linthorst GE, Wijburg FA, Hollak CE: Vasculopathy in patients with Fabry disease: current controversies and research directions. Mod Genet Metab. 2010, 99:99-108. 10.1007/s00415-004-0364-9
23. Feldt-Rasmussen U: Fabry disease and early stroke. Stroke Res Treat. 2011, 2011:615218. 10.4061/2011/615218
24. Sims K, Politi J, Banikazemi M, Lee P: Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events: natural history data from the Fabry Registry. Stroke. 2009, 40:788-94. 10.1161/STROKEAHA.108.526295
25. Lee TH, Yang JT, Lee JD, et al.: Genomic screening of Fabry disease in young stroke patients: the Taiwan experience and a review of the literature. Eur J Neurol. 2019, 26:998-1003. 10.1111/ene.13775
26. Rolfs A, Fazekas F, Grittner U, et al.: Acute cerebrovascular disease in the young: the Stroke in Young Fabry Patients study. Stroke. 2013, 44:340-9. 10.1161/STROKEAHA.112.663708
27. Song Y, Mans J, Cook NR, Albert CM, Buring JE, Liu S: Dietary magnesium intake and risk of cardiovascular disease among women. Am J Cardiol. 2005, 96:1155-1160. 10.1016/j.amjcard.2005.06.045
28. Sheng S, Wu L, Nalleballe K, et al.: Fabry’s disease and stroke: effectiveness of enzyme replacement therapy (ERT) in stroke prevention, a review with meta-analysis. J Clin Neurosci. 2019, 65:83-8. 10.1016/j.jocn.2019.05.004
29. Ortiz A, Ahsioe A, Bichet DG, et al.: Time to treatment benefit for adult patients with Fabry disease receiving agalsidase β: data from the Fabry Registry. J Med Genet. 2016, 53:495-502. 10.1136/jmedgenet-2015-105486